[{"text": "Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron\u00ae in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 Dogwood Therapeutics, Inc. Tue, Jan 21, 2025, 5:15 PM 4 min read In This Article: DWTX +13.53% Dogwood Therapeutics, Inc. ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the \u201cCompany\u201d), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron \u00ae Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron \u00ae to treat neuropathic pain associated with prior chemotherapy treatment (\u201cCINP\u201d) is expected to occur in the first quarter of 2025. Halneuron \u00ae is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron \u00ae treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron \u00ae has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies, with no addiction potential. \u201cChemotherapy is effective, but can be very challenging for patients given common side effects, including fever, fatigue, infection, hair loss, neuropathy and pain,\u201d commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Dogwood Therapeutics, Inc. \u201cResearch suggests that one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off label treatment with available analgesics is generally not effective. Further, market data suggest that approximately one-in-three cancer patients are treated with opioids.\u201d \u201cThe lead Halneuron \u00ae target indication in CINP represents an area of high unmet medical need and a market valued at approximately $1.5B,\u201d said Greg Duncan, Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc. \u201cThe Dogwood executive team has established a track record of developing and/or commercializing blockbuster medicines, including the pain therapeutics Celebrex, Lyrica and Savella.\u201d About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron \u00ae which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron \u00ae treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (\u201cFM\u201d) and Long-COVID (\u201cLC\u201d). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo clinical trials and in both cases demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research. Story Continues For more information, please visit www.dwtx.com . Follow Dogwood Therapeutics Email Alerts: https://ir.dwtx.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/dogwoodther/ Twitter: https://twitter.com/dogwoodther Facebook: https://www.facebook.com/dogwoodther Forward-Looking Statements Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \"will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood\u2019s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company\u2019s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Contact: IR@dwtx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2025-01-21T14:15:00+00:00", "sentiment": {"score": 0.23753255791962147, "confidence": 0.2610609829425812, "probabilities": {"positive": 0.2610609829425812, "negative": 0.02352842502295971, "neutral": 0.715410590171814}}, "embedding": [-0.0852750614285469, -0.19577941298484802, 0.10602426528930664, 0.019689030945301056, -0.1837226152420044, -0.1398046761751175, -0.1621829867362976, 0.20156356692314148, 0.1926880031824112, 0.03953110799193382, -0.04210294038057327, 0.12425564974546432, 0.1214720606803894, 0.11635251343250275, -0.12576670944690704, 0.10565385222434998, 0.15199074149131775, 0.09716428071260452, 0.0011844374239444733, 0.15611153841018677, -0.005877690389752388, 0.02752402052283287, 0.03574163466691971, 0.06400083750486374, -0.15247851610183716, 0.05764384940266609, -0.04141431301832199, 0.03571242839097977, -0.14316831529140472, 0.0005815336480736732, 0.1730491816997528, 0.08932538330554962, -0.08889225125312805, 0.0818590372800827, -0.005244607105851173, 0.021357715129852295, -0.22300946712493896, 0.03214341029524803, -0.02635778859257698, 0.06429982930421829, -0.04296533390879631, 0.05845825374126434, -0.08884334564208984, 0.03706368803977966, 0.18695887923240662, -0.2296338677406311, -0.15984755754470825, -0.11246781051158905, 0.006346466485410929, 0.18721511960029602, 0.032404184341430664, -0.018053319305181503, 0.05896701291203499, 0.14140793681144714, 0.05598270893096924, -0.1091061532497406, -0.21162322163581848, -0.010102969594299793, 0.010502996854484081, 0.026940686628222466, 0.05320887640118599, -0.03706147149205208, 0.12063783407211304, -0.08529467135667801, 0.08434794098138809, 0.18219797313213348, -0.09963338077068329, -0.15837135910987854, 0.001118069514632225, -0.10993322730064392, -0.08071477711200714, -0.04826904088258743, 0.039680104702711105, 0.012634599581360817, -0.02129390463232994, -0.11412730813026428, 0.12018100917339325, 0.08113890886306763, 0.0761859118938446, -0.14254450798034668, 0.010890649631619453, 0.17594552040100098, 0.0936431735754013, 0.15243364870548248, 0.10377148538827896, -0.016164667904376984, 0.10151279717683792, 0.22731974720954895, -0.04184743016958237, 0.008236737921833992, 0.10278329998254776, 0.0569324865937233, -0.1368429958820343, 0.06585650146007538, -0.08983489871025085, -0.17254367470741272, -0.23293712735176086, 0.039791084825992584, -0.1417599618434906, 0.009981733746826649, 0.0918714851140976, 0.005642574280500412, -0.23360145092010498, -0.2181658148765564, 0.061939265578985214, -0.025693465024232864, 0.1654868870973587, -0.003615589812397957, -0.11299805343151093, 0.022578120231628418, -0.08089080452919006, -0.00823744386434555, -0.20357964932918549, 0.09120859205722809, 0.019443362951278687, 0.15162046253681183, 0.04887847602367401, 0.04423179477453232, 0.23075005412101746, -0.045416221022605896, 0.017327485606074333, -0.12752245366573334, -0.04115423560142517, -0.058151356875896454, -0.03842964023351669, 0.1721336841583252, -0.10448163002729416, 8.259511139032983e-33, -0.012280396185815334, -0.03204760327935219, -0.0678800493478775, -0.08445428311824799, -0.0057645533233881, -0.06141062080860138, 0.03474210947751999, 0.091138556599617, -0.12261877954006195, -0.19375285506248474, -0.13261598348617554, 0.05565575510263443, 0.06752090156078339, 0.00993574969470501, -0.00880284234881401, -0.11784738302230835, 0.010949920862913132, -0.09695784002542496, 0.06718612462282181, -0.13444915413856506, 0.06829586625099182, 0.02208581753075123, -0.07498413324356079, 0.12265215814113617, -0.09209400415420532, 0.024747520685195923, -0.16477081179618835, 0.08276713639497757, 0.12798133492469788, -0.0002044960856437683, -0.1595720499753952, -0.1837240755558014, 0.062091559171676636, -0.08601438999176025, -0.16953358054161072, 0.0943417027592659, -0.09957815706729889, -0.051240473985672, -0.06973697245121002, 0.0490841418504715, -0.06013146787881851, 0.08775507658720016, -0.08659456670284271, -0.0003902008756995201, 0.06029249727725983, -0.05601322650909424, -0.19305896759033203, 0.019919652491807938, -0.004925481975078583, -0.06513148546218872, -0.04183974862098694, 0.07793323695659637, 0.12747421860694885, -0.08638742566108704, -0.06917533278465271, 0.0029441185761243105, -0.026021653786301613, 0.034370116889476776, 0.18365827202796936, 0.11485680192708969, 0.027276262640953064, -0.0777786374092102, -0.02685900218784809, -0.007739395834505558, 0.027968501672148705, 0.17268821597099304, -0.11249561607837677, -0.054667338728904724, -0.16362574696540833, 0.025451406836509705, -0.08068142831325531, 0.006098317913711071, 0.1211114376783371, 0.10908558964729309, -0.01631178893148899, -0.022745126858353615, 0.05321621149778366, 0.046771496534347534, -0.04612711817026138, 0.08072684705257416, -0.008751326240599155, -0.06572257727384567, -0.12895429134368896, 0.21885597705841064, 0.042695723474025726, -0.03302440047264099, 0.002454280387610197, -0.03625450283288956, -0.12855488061904907, -0.013204553164541721, 0.13236749172210693, -0.06651545315980911, -0.04275544732809067, 0.10183311998844147, 0.1317255198955536, -9.279493464713236e-33, -0.06320042163133621, 0.14900916814804077, 0.06422193348407745, -0.011598825454711914, -0.06226659193634987, 0.20782184600830078, -0.0597536526620388, -0.2394246906042099, 0.08464711159467697, -0.10275053977966309, 0.10530823469161987, 0.04618191719055176, -0.10450674593448639, 0.004024515859782696, -0.16546933352947235, 0.009155690670013428, -0.16529017686843872, 0.08602020144462585, -0.007872380316257477, -0.007781916297972202, 0.051183246076107025, 0.310072660446167, -0.14220380783081055, 0.09567158669233322, -0.04494818300008774, 0.11873447895050049, 0.14197571575641632, -0.010840465314686298, 0.01592162251472473, 0.04428243264555931, 0.04143786430358887, 0.05744658410549164, -0.123763307929039, -0.11480318009853363, -0.040863197296857834, 0.15924806892871857, 0.0428750216960907, -0.14210748672485352, -0.22166743874549866, -0.02528628520667553, 0.04511801898479462, -0.028775129467248917, -0.05782127007842064, 0.11346778273582458, 0.019335243850946426, 0.08750840276479721, 0.06622577458620071, -0.10580188781023026, 0.04346511885523796, 0.14557388424873352, -0.0033701136708259583, 0.1384071409702301, 0.05519565939903259, 0.08728119730949402, 0.07145950198173523, 0.041268013417720795, -0.0837760716676712, -0.034455664455890656, 0.061741702258586884, -0.06291888654232025, -0.05547655373811722, 0.034332115203142166, 0.09296232461929321, -0.09381499141454697, 0.081207275390625, 0.0013288706541061401, -0.06659872829914093, 0.07625709474086761, 0.15132014453411102, -0.15981453657150269, -0.20010128617286682, 0.12331951409578323, -0.009794028475880623, -0.09633149206638336, -0.0688457041978836, 0.17664474248886108, -0.003437718376517296, -0.1606089472770691, -0.08583424985408783, -0.002788628451526165, -0.08026304841041565, -0.041910238564014435, -0.008102469146251678, 0.121315598487854, -0.0642884224653244, 0.029913974925875664, 0.1340339183807373, 0.10695069283246994, -0.10705533623695374, -0.03188580274581909, 0.08269979804754257, -0.06454958766698837, -0.10365015268325806, 0.11888213455677032, -0.11761370301246643, -1.0027109453858429e-07, -0.05897824093699455, -0.04206612706184387, -0.05472407117486, -0.07370329648256302, 0.05612685903906822, 0.0243389829993248, -0.058290764689445496, -0.06043371558189392, -0.2560974359512329, 0.16274718940258026, 0.14149950444698334, 0.10756446421146393, -0.07894451916217804, 0.026809804141521454, -0.09921712428331375, 0.15747475624084473, 0.09302032738924026, 0.09204807877540588, 0.10560797154903412, 0.15289363265037537, -0.16402262449264526, -0.09419864416122437, 0.03669168800115585, -0.08275513350963593, 0.10384348034858704, -0.0960819274187088, 0.05806168168783188, 0.10780653357505798, 0.00023147329920902848, -0.13582763075828552, -0.05560948699712753, 0.047343671321868896, 0.06614240258932114, -0.02825614996254444, -0.04393964260816574, 0.029257310554385185, 0.03794194012880325, 0.08986497670412064, -0.03222673013806343, 0.037495315074920654, 0.023793857544660568, 0.028768962249159813, -0.08188173919916153, 0.08028770983219147, 0.0038984008133411407, -0.03753544017672539, 0.04676641523838043, 0.06976892054080963, 0.0006445699837058783, -0.09890678524971008, -0.04686089977622032, 0.04700833186507225, 0.019086915999650955, -0.10191965103149414, -0.1062556579709053, 0.15604250133037567, -0.10282573103904724, -0.09972492605447769, 0.017542919144034386, -0.12775322794914246, 0.07253541797399521, -0.17441686987876892, 0.033183492720127106, -0.009833922609686852], "changes": {"1wk": 452.3809235472626}}, {"text": "DWTX: Phase 2 Long COVID Results Expected Soon Zacks Small Cap Research Mon, Nov 11, 2024, 3:00 PM 8 min read In This Article: DWTX +13.53% By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is advancing IMC-2 (valacyclovir + celecoxib) as a treatment for Long COVID. The drug is currently being evaluated in a Phase 2a clinical trial being conducted by the Bateman Horne Center (BHC). Dogwood previously supplied the BHC with an unrestricted investigational grant to fund the ongoing 12-week, placebo controlled study of the valacyclovir/celecoxib combination in up to 60 Long COVID patients across three treatment arms: Val/Cel 750mg/200mg BID (1.5g/400mg per day) Val/Cel 1500mg/200mg BID (3.0g/400mg per day) Placebo The company announced that enrollment of the Phase 2a trial had completed in July 2024 and recently confirmed that topline data are expected in mid-November 2024. Previously, the company announced it had reached alignment with the U.S. Food and Drug Administration (FDA) on the requirements for advancing IMC-2 as a treatment for Long COVID. The FDA agreed that for the Phase 2 study, Dogwood can use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint. In addition, the FDA would like Dogwood to evaluate a range of IMC-2 doses, which includes valacyclovir doses above presently approved dosage strengths. Previously, the BHC conducted an open label, proof-of-concept trial of IMC-2 in patients with Long COVID and showed that patients experienced clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction. Importantly, the combination of valacyclovir/celecoxib was well tolerated as there were no serious adverse events and the side effect profile was consistent with what is known for both valacyclovir and celecoxib. The following table gives an overview of the results for various study endpoints examined, the majority of which statistically significantly favored valacyclovir/celecoxib. For a full analysis of those results please see our previous report here . While we believe the treatment of Long COVID is a compelling opportunity, it is difficult to get an accurate assessment of the total number of individuals who are suffering from the condition. A 2023 survey by the Centers for Disease Control (CDC) estimated that the prevalence of Long COVID in U.S. adults went from 7.5% in 2022 to 6.0% in 2023, but remained unchanged during 2023 ( Ford et al ., 2023 ). Importantly, approximately one-quarter of adults in that survey reported significant activity limitations due to Long COVID. This is translating into a severe economic cost, including an estimated approximately $500 billion in increased medical expenses ( Cutler, 2022 ). Story Continues Virios Combines with Wex Pharmaceuticals to Form Dogwood Therapeutics In October 2024, Virios Therapeutics, Inc. (VIRI) announced a business combination with privately-held Wex Pharmaceuticals, Inc. to form Dogwood Therapeutics, Inc. (DWTX). The combined company will be focused on the clinical development of three assets: Halneuron\u00ae, which is currently in a Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain (CINP); IMC-1, a Phase 3-ready asset for the treatment of fibromyalgia; and IMC-2, which is currently in a Phase 2 trial for the treatment of Long COVID. Halneuron\u00ae The lead asset for Dogwood is Halneuron (tetrodotoxin, TTX), a sodium channel blocker currently in a Phase 2b clinical trial for the treatment of CINP. TTX was originally discovered in the pufferfish and subsequent research has identified the toxin in 13 phyla (in both Eukarya and Bacteria ) that includes both marine and terrestrial eukaryotes ( Lago et al ., 2015 ). As a natural poison, TTX is extremely effective and is the most potent non-peptide neurotoxin known. It blocks the influx of sodium through voltage-gated sodium channels (Na V s), thereby preventing the initiation and propagation of action potentials in almost all neurons and muscle cells ( Stevens et al ., 2011 ). Mammals possess nine voltage-gated sodium channels, Na V 1.1-Na V 1.9. TTX binds to Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.4, Na V 1.6, and Na V 1.7 ( Nieto et al ., 2012 ). Na V 1.7 is expressed in all types of dorsal root ganglion (DRG) neurons, sympathetic neurons, Schwann cells, and neuroendocrine cells ( Catterall et al ., 2005 ). It is responsible for the perception of pain, which is supported by multiple lines of evidence. Individuals with loss-of-function mutations in the SCN9A gene (which encodes the alpha-subunit of Na V 1.7) experience a complete inability to sense pain ( Cox et al ., 2006 ) while those with a gain-of-function mutation in SCN9A experience erythromelalgia ( Dib-Hajj et al ., 2005 ). In animal models, Na V 1.7 nociceptor-specific knockout mice showed increased mechanical and thermal pain thresholds ( Nassar et al ., 2004 ). These results led researchers to hypothesize that TTX could be a potential therapeutic to control pain. Halneuron Clinical Trials The latest clinical trials investigating Halneuron include a Phase 2 cancer related pain (CRP) study and a Phase 2 CINP trial. Phase 2 CRP Trial This was a randomized, double blind, parallel design, multicenter trial that enrolled 165 patients with moderate to severe inadequately controlled CRP. All patients were on standard of care pain management. Halneuron or placebo was administered twice a day for four days and all patients recorded their pain response from days 5-8 (early post-injection period) and from days 9-15 (late post-injection period). The results showed a statistically significant improvement in pain outcomes for Halneuron, with 51% of Halneuron patients experiencing a \u226530% reduction in pain compared to only 35% in the placebo group, as shown in the following image. For Global Impression of Pain Change, 55% of Halneuron patients reported an improvement in pain compared to 24% of placebo patients. Conversely, 70% of placebo patients reported no change or worse pain compared to only 37% of patients. In addition to a positive pain response, the duration of pain relief was much higher for Halneuron patients, as shown in the following figure. The average pain response for Halneuron responders was 57.7 days compared to 10.5 days for placebo responders. Lastly, over one-quarter of Halneuron responders (27%) had pain relief that lasted for 30 days or longer after one cycle of treatment. Phase 2 CINP Trial This was a randomized, double blind, dose-finding, placebo controlled, multicenter study in patients with CINP. Various doses of Halneuron were tested over four days of treatment followed by measurement over four weeks. The study included a total of 125 patients across five dosing cohorts (four active and one placebo). The results showed that a dose of 30 \u03bcg twice per day for four days demonstrated the highest level of pain reduction compared to placebo, with the responder analysis results given below. Halneuron is currently being evaluated in a Phase 2b clinical trial for CINP. We anticipate an update from the company on the trial in the first half of 2025 an interim data readout in the second half of 2025. Background on CINP CINP is the result of injury to the somatosensory nervous system following chemotherapy treatment ( Colvin, 2019 ). For agents such as paclitaxel and oxaliplatin, the rate of CINP is up to 81% and 98%, respectively ( Hershman et al ., 2010 ; Gebremedhn et al ., 2018 ). CINP begins as an acute pain syndrome that coincides with drug administration, however it can progress to a chronic condition following multiple rounds of therapy. The only drug endorsed to treat CINP by the American Society of Clinical Oncology (ASCO) is duloxetine, which showed a significant reduction in pain in a Phase 3 clinical trial ( Lavoie Smith et al ., 2013 ). However, the drug is not FDA approved for the treatment of CINP. In addition, in a preclinical oxaliplatin-induced neuropathic pain model, Halneuron was superior to duloxetine based on the paw withdrawal threshold (PWT), a measure of pain tolerance. Financial Update On November 7, 2024, Dogwood announced financial results for the third quarter of 2024. As expected, the company did not report any revenues for the third quarter of 2024. R&D expenses for the three months ending September 30, 2024 were $0.5 million compared to $0.4 million for the third quarter of 2023. The increase was primarily due to increases in expenses associated with the grant to BHC for the Phase 2 trial in Long Covid. G&A expenses for the third quarter of 2024 were $1.8 million compared to $0.9 million for the third quarter of 2023. The increase was primarily due to higher legal and professional fees partially offset by lower insurance expenses. As of September 30, 2024, Dogwood had approximately $2.0 million in cash and cash equivalents. This does not include the $16.5 million in loan proceeds received on October 7, 2024. We also anticipate an additional $3.0 million of loan proceeds will be received by the company in February 2025. This should be sufficient to fund operations through the end of 2025. As of November 6, 2024, Dogwood had approximately 1.3 million common shares outstanding and, when factoring in stock options, warrants, and the Series A convertible shares, a fully diluted share count of approximately 23.6 million. Conclusion We look forward to the topline data from the Phase 2 trial of IMC-2 in Long COVID in the next couple of weeks. In addition, we anticipate an update from the company regarding the Phase 2b trial of Halneuron in the first half of 2025 and interim results from the study should be available in the second half of 2025. With no changes to our model our valuation remains at $11.50. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to\u00a0receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-11-11T12:00:00+00:00", "sentiment": {"score": 0.6188663775101304, "confidence": 0.6307457685470581, "probabilities": {"positive": 0.6307457685470581, "negative": 0.0118793910369277, "neutral": 0.3573749363422394}}, "embedding": [-0.040089309215545654, -0.1407964825630188, 0.00039430567994713783, 0.001917433924973011, -0.05033896863460541, -0.04384731128811836, -0.15931732952594757, 0.28002166748046875, 0.16181044280529022, 0.0005070073530077934, -0.10840584337711334, 0.04791310802102089, 0.09690430015325546, 0.06088792160153389, -0.002757769078016281, 0.03311987221240997, 0.1123548299074173, 0.0529506653547287, -0.04666050896048546, 0.0799475908279419, 0.00017466582357883453, -0.03876625373959541, 0.024537259712815285, 0.06551947444677353, -0.15040360391139984, 0.04929960519075394, -0.16240273416042328, 0.014894193969666958, -0.04774020239710808, -0.060679301619529724, 0.12549516558647156, 0.19292040169239044, 0.004491724073886871, -0.08819986879825592, -0.05515659600496292, -0.004495665431022644, -0.03945600986480713, -0.034022457897663116, -0.1008877232670784, -0.04926469177007675, -0.01119890809059143, 0.06360457837581635, -0.06648383289575577, 0.010213473811745644, 0.05272068828344345, -0.07462310791015625, -0.15425316989421844, -0.04773348197340965, -0.005247881170362234, 0.15572410821914673, -0.05284629017114639, -0.08611650764942169, 0.02332766354084015, 0.11415310204029083, -0.12696468830108643, -0.003935750108212233, -0.22210711240768433, 0.005928697530180216, 0.06523972749710083, 0.11006473004817963, -0.012270744889974594, 0.06627374142408371, 0.06149647384881973, 0.031691648066043854, 0.06180505454540253, 0.09595000743865967, -0.041167933493852615, -0.10371382534503937, 0.07443084567785263, -0.019728485494852066, -0.031154803931713104, -0.08273927867412567, -0.04406090825796127, -0.035359688103199005, 0.009249212220311165, 0.04625978693366051, 0.1161419004201889, -0.013926503248512745, 0.20986858010292053, -0.19524817168712616, -0.060876261442899704, 0.09652864187955856, 0.12718671560287476, 0.0839255154132843, -0.007160646375268698, -0.046294622123241425, 0.05966615676879883, 0.2106936126947403, -0.001196535537019372, 0.044346749782562256, 0.2476160228252411, 0.022210625931620598, -0.06945870816707611, 0.0775139108300209, 0.13079741597175598, -0.02472921647131443, -0.11182665824890137, 0.07862825691699982, -0.018054401502013206, -0.06163863092660904, -0.013475919142365456, -0.04659299552440643, -0.14947503805160522, -0.03941967338323593, 0.006479117088019848, -0.1457756906747818, 0.1383957713842392, 0.028246046975255013, -0.014840040355920792, -0.07966002821922302, -0.012710986658930779, 0.05419110506772995, 0.03492491692304611, 0.0017744649667292833, -0.027907872572541237, 0.21542134881019592, 0.01001167856156826, -0.0024719792418181896, 0.17247702181339264, -0.09425196051597595, 0.13116829097270966, -0.04195073992013931, 0.052510105073451996, -0.127711221575737, 0.027758412063121796, 0.01596260629594326, 0.0010638367384672165, 1.584544050515778e-32, -0.05777886509895325, 0.006527097430080175, 0.09422539174556732, 0.04265006631612778, -0.10211087763309479, -0.00034654990304261446, 0.002693832851946354, 0.11444514244794846, -0.040927644819021225, -0.1232413798570633, -0.1151752695441246, 0.10971984267234802, 0.02502695471048355, 0.07448127865791321, -0.014140181243419647, -0.10896170139312744, -0.01442310307174921, 0.03387664631009102, -0.05305096507072449, 0.08922301232814789, 0.13627111911773682, -0.03658347576856613, 0.014603452757000923, 0.12246495485305786, 0.0037625639233738184, 0.06691551208496094, -0.0502128005027771, 0.09298953413963318, -0.051444411277770996, 0.06015755981206894, -0.1557597666978836, -0.058253876864910126, 0.08820372074842453, 0.004827738273888826, -0.1587866246700287, 0.022586453706026077, -0.047618843615055084, -0.06448105722665787, 0.006189277395606041, 0.12598365545272827, 0.03934584930539131, 0.1211751401424408, -0.02432440221309662, -0.014147131703794003, 0.011055678129196167, -0.1534789800643921, -0.16574296355247498, 0.015310666523873806, -0.1384791135787964, -0.026302073150873184, -0.031823839992284775, 0.07372293621301651, -0.01263994537293911, -0.10285034775733948, -0.044942259788513184, 0.13795681297779083, -0.03641941398382187, 0.05706591531634331, 0.0605548620223999, 0.16929411888122559, 0.04526994377374649, 0.10171908140182495, -0.0446501299738884, 0.013193542137742043, -0.008504626341164112, 0.019638579338788986, -0.019814925268292427, -0.0639597699046135, -0.25954508781433105, -0.022440757602453232, -0.0038159750401973724, -0.0006135592702776194, 0.13130059838294983, 0.03872727230191231, 0.11525039374828339, -0.09767179191112518, 0.05069119110703468, 0.10470123589038849, -0.054415784776210785, -0.14089959859848022, -0.061523906886577606, -0.02712097018957138, -0.011759642511606216, 0.16306567192077637, 0.051012903451919556, -0.104657381772995, -0.03487935662269592, 0.030980184674263, -0.23593831062316895, -0.01076227705925703, -0.012127134948968887, -0.030716337263584137, 0.0010123038664460182, 0.12888118624687195, 0.05157335847616196, -1.4108280259833218e-32, -0.08984467387199402, -0.034394387155771255, -0.06217867508530617, -0.024986103177070618, 0.011815919540822506, 0.20216219127178192, 0.13925862312316895, -0.15417692065238953, 0.18775154650211334, -0.08565785735845566, 0.15105022490024567, 0.04993031546473503, -0.10501568019390106, -0.030636627227067947, -0.18516355752944946, 0.03575320914387703, -0.017877452075481415, 0.0051848697476089, -0.16567166149616241, 0.023294249549508095, 0.09480880945920944, 0.12845845520496368, -0.07292646169662476, 0.03921965882182121, 0.03062264993786812, 0.0944044440984726, 0.1119961366057396, -0.016155341640114784, 0.05344942957162857, -0.01681009866297245, -0.012857324443757534, -0.026160424575209618, -0.14789411425590515, -0.012316007167100906, -0.027959508821368217, 0.060690734535455704, 0.05936511605978012, -0.2152479588985443, -0.1308344304561615, -0.04495871067047119, 0.0776219293475151, 0.04558560252189636, -0.08161083608865738, -0.06485825031995773, 0.08100959658622742, 0.05581112205982208, 0.09243933111429214, -0.13275441527366638, 0.1873842179775238, 0.1066637933254242, -0.05230742320418358, -0.012962435372173786, -0.020079119130969048, 0.17391283810138702, -0.062074411660432816, -0.0658816397190094, 0.008893250487744808, -0.029106847941875458, -0.06872325390577316, 0.006039058789610863, 0.0013344534672796726, 0.13579513132572174, 0.028913913294672966, -0.06645005941390991, 0.15060733258724213, 0.0451410673558712, -0.0317060612142086, 0.05089974030852318, 0.14790773391723633, -0.19794942438602448, -0.041325777769088745, -0.055546507239341736, -0.0640062540769577, -0.1082453578710556, -0.06745757162570953, 0.1172209233045578, 0.007992828264832497, -0.19496425986289978, -0.018337823450565338, -0.13308170437812805, -0.1056583970785141, -0.1301662027835846, -0.00429201778024435, 0.03662382811307907, -0.0008645616471767426, 0.0011451246682554483, -0.029099129140377045, -0.011042949743568897, 0.019050566479563713, 0.025001119822263718, -0.09691691398620605, -0.10793358087539673, -0.023546233773231506, 0.0598461851477623, 0.04642853885889053, -1.0030549191242244e-07, 0.05296371877193451, 0.005119483917951584, -0.0384092852473259, 0.0071158637292683125, 0.028995508328080177, 0.014713694341480732, -0.14147832989692688, 0.009026456624269485, -0.08684126287698746, 0.16710281372070312, 0.13612645864486694, 0.10480806231498718, -0.02919185534119606, -0.0830865204334259, -0.14213477075099945, 0.16162042319774628, 0.036925677210092545, -0.023155495524406433, 0.02225944958627224, -0.01110399141907692, -0.14116357266902924, -0.13740473985671997, -0.0038773734122514725, -0.18382255733013153, 0.03303731605410576, -0.1247277557849884, 0.062437646090984344, 0.07668301463127136, 0.03677947074174881, -0.12224474549293518, -0.07596774399280548, -0.013399027287960052, -0.03802599757909775, -0.05452006682753563, 0.024767402559518814, -0.05300500616431236, 0.02769777737557888, 0.1362646520137787, 0.11679182946681976, 0.26096922159194946, 0.02597096934914589, -0.0073415180668234825, -0.11052929610013962, 0.05390080437064171, 0.08644214272499084, 0.03233809769153595, -0.1205926239490509, -0.00417114095762372, 0.017480969429016113, -0.09873208403587341, -0.057832203805446625, 0.031240342184901237, -0.005696811247617006, -0.04861096292734146, -0.10741277039051056, 0.2087479680776596, -0.037616096436977386, -0.11152300238609314, 0.121487095952034, -0.14541372656822205, -0.01657373085618019, -0.11051362752914429, 0.04382571950554848, 0.031763166189193726], "changes": {"1wk": -13.15789583757421, "1mo": -19.883042444083177}}, {"text": "PREMIUM Wall Street Set to Open Mixed Tuesday Ahead of Holiday Break MT Newswires Tue, Dec 24, 2024, 5:11 PM 2 min read US stocks look set to open mixed in Tuesday's shortened trading session, ahead of the Christmas holi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-12-24T14:11:39+00:00", "sentiment": {"score": 0.05504593066871166, "confidence": 0.06995084136724472, "probabilities": {"positive": 0.06995084136724472, "negative": 0.014904910698533058, "neutral": 0.9151443243026733}}, "embedding": [-0.03133916109800339, -0.11873901635408401, 0.05090978741645813, 0.23458626866340637, 0.07267993688583374, 0.04929995909333229, -0.10717175900936127, -0.1585746854543686, -0.13598273694515228, -0.08379092067480087, 0.0073662009090185165, 0.24813534319400787, -0.21444280445575714, -0.03594422712922096, 0.28823357820510864, 0.0275439340621233, -0.0745728388428688, -0.10008107870817184, -0.08537851274013519, 0.179924875497818, -0.0892150029540062, -0.16625382006168365, -0.21466165781021118, -0.09118287265300751, -0.018911438062787056, 0.0683063268661499, -0.02844417281448841, 0.039525777101516724, 0.061160266399383545, -0.12470011413097382, -0.04053366184234619, -0.008185790851712227, 0.0975366160273552, -0.01358798984438181, -0.004125926643610001, -0.09690018743276596, 0.05305647477507591, 0.029650764539837837, 0.17633871734142303, 0.024629877880215645, 0.1533929854631424, -0.21533310413360596, -0.06862907856702805, 0.04124332591891289, 0.018787816166877747, -0.02231670171022415, 0.02201634645462036, -0.021289410069584846, 0.07839050143957138, -0.016408979892730713, 0.047870516777038574, 0.02506663091480732, -0.08139525353908539, -0.062486618757247925, -0.13758838176727295, 0.08320465683937073, -0.0870865136384964, -0.036780912429094315, 0.15614351630210876, -0.0551588274538517, -0.13131332397460938, -0.03841414675116539, -0.07062292844057083, 0.19362831115722656, 0.07586632668972015, 0.04813661053776741, -0.09287378937005997, 0.22582963109016418, 0.04878503829240799, -0.16802018880844116, 0.051363151520490646, 0.1532895416021347, -0.05366680771112442, -0.034487076103687286, 0.005619020666927099, 0.15151646733283997, 0.10883759707212448, -0.13275188207626343, -0.06230907514691353, -0.07235190272331238, -0.02217649295926094, -0.2016303688287735, -0.11457758396863937, -0.008229049853980541, 0.0647905096411705, 0.059263575822114944, -0.13334587216377258, -0.0569484680891037, -0.004256891086697578, -0.08392131328582764, -0.023951131850481033, 0.034203775227069855, -0.07532909512519836, 0.06569677591323853, -0.09727270156145096, -0.03625091165304184, -0.11922065168619156, -0.08496170490980148, -0.044085919857025146, 0.15078559517860413, 0.11398182064294815, 0.11134789139032364, -0.005327653139829636, 0.10901575535535812, -0.052949126809835434, -0.1344706118106842, -0.08318646252155304, 0.16524550318717957, -0.07677273452281952, -0.07867661118507385, 0.06986037641763687, 0.013363095000386238, 0.13196627795696259, -0.30592915415763855, -0.14712713658809662, 0.1323585957288742, -0.1698734164237976, -0.07619426399469376, 0.14998148381710052, 0.013427050784230232, 0.012975689023733139, 0.20295350253582, -0.11295400559902191, -0.1361226886510849, -0.04725513234734535, 0.07541728764772415, 0.15440942347049713, 1.2413074877257442e-32, -0.10035216808319092, -0.06947726756334305, -0.04818390682339668, -0.045274924486875534, 0.13326597213745117, 0.006109035108238459, -0.05362185090780258, -0.0793667808175087, -0.10315282642841339, 0.0712590292096138, 0.03858543932437897, 0.11777200549840927, -0.135623037815094, 0.05704173818230629, -0.09750058501958847, -0.16299045085906982, 0.04473530501127243, -0.0006063610198907554, 0.05477066710591316, 0.045663315802812576, 0.0677705854177475, -0.155018612742424, -0.13513225317001343, -0.052904512733221054, -0.10573753714561462, -0.02792406640946865, 0.2290988564491272, 0.00820332020521164, 0.11061122268438339, 0.10488314926624298, -0.10339150577783585, 0.09450841695070267, 0.05826881155371666, 0.2038063406944275, 0.10007364302873611, 0.1461993157863617, -0.14321434497833252, 0.018856925889849663, 0.008076556026935577, -0.18007369339466095, 0.1020040512084961, -0.10266679525375366, -0.20984436571598053, -0.04952371120452881, 0.10730703175067902, 0.08063805103302002, 0.0004944202955812216, -0.005128767341375351, 0.06722350418567657, 0.0037193798925727606, -0.047506701201200485, 0.09514989703893661, -0.295980304479599, 0.03246769681572914, -0.09614754468202591, -0.051712870597839355, -0.03185678645968437, -0.1256357580423355, 0.052974238991737366, -0.04485796019434929, 0.18136243522167206, 0.13123783469200134, -0.050824567675590515, -0.1071343943476677, -0.2630043625831604, 0.25657787919044495, -0.026056654751300812, 0.032559834420681, -0.17411202192306519, 0.00556778721511364, 0.13357029855251312, -0.03712695091962814, 0.08524186909198761, -0.02025493234395981, -0.05615204945206642, 0.17313507199287415, -0.07775375992059708, 0.10085736960172653, 0.34159696102142334, 0.10570560395717621, 0.23635798692703247, 0.07381012290716171, 0.23764155805110931, 0.06488174945116043, -0.049241311848163605, 0.06564299017190933, -0.03535732626914978, -0.008028163574635983, -0.08025574684143066, -0.0025568262208253145, -0.1336548626422882, 0.060464296489953995, 0.04911328852176666, 0.22240050137043, 0.038004931062459946, -1.653171614768691e-32, -0.08846808224916458, -0.08024071156978607, -0.06525105237960815, 0.02895074523985386, -0.14173871278762817, 0.03028395213186741, -0.030970266088843346, 0.13613997399806976, 0.27775338292121887, 0.30420124530792236, 0.1555638164281845, 0.1301167607307434, -0.09130895882844925, 0.008561578579246998, 0.056439872831106186, -0.11015189439058304, 0.18218664824962616, 0.17844261229038239, 0.0403817817568779, 0.12949804961681366, -0.08110442757606506, 0.038625773042440414, -0.1624174267053604, 0.14267277717590332, 0.3000616133213043, -0.028635680675506592, 0.12354229390621185, 0.09152905642986298, 0.038352131843566895, 0.01079095620661974, -0.18130391836166382, -0.13970129191875458, -0.12687194347381592, 0.11249668896198273, -0.027677150443196297, 0.048222485929727554, 0.11551077663898468, 0.06288548558950424, 0.007639720104634762, -0.028365133330225945, 0.027158860117197037, -0.14073003828525543, -0.12791557610034943, 0.1571771800518036, 0.0881592407822609, 0.1307983547449112, -0.10924539715051651, -0.08148623257875443, -0.027091341093182564, 0.013354036025702953, -0.11598395556211472, 0.18821313977241516, 0.006178643554449081, 0.00032912526512518525, -0.11678232997655869, -0.002692464040592313, -0.03752579912543297, 0.05533652380108833, -0.06730236113071442, -0.07037637382745743, 0.0627642422914505, 0.10236147791147232, -0.1428501158952713, -0.15037362277507782, -0.025864582508802414, -0.13006272912025452, 0.02585410326719284, -0.20185397565364838, -0.05270171910524368, 0.016280220821499825, 0.005996210966259241, -0.05823994055390358, -0.11314253509044647, -0.2981635332107544, -0.08662337064743042, 0.13754130899906158, 0.11908707767724991, 0.015095017850399017, -0.1064031794667244, 0.15384763479232788, -0.0549999475479126, -0.025518665090203285, -0.07718023657798767, -0.005729250609874725, -0.033560048788785934, -0.0057061538100242615, -0.06803084909915924, 0.11328773945569992, -0.1057361364364624, 0.05708588659763336, -0.179662823677063, -0.02471030503511429, -0.09186681360006332, 0.09330934286117554, -0.13468202948570251, -1.0020965390822312e-07, 0.09180741012096405, -0.09551551192998886, -0.002668364904820919, 0.05585600435733795, 0.02808229997754097, -0.02175068110227585, -0.03272367641329765, -0.2518109679222107, 0.06603199988603592, 0.19220872223377228, 0.061812616884708405, 0.06623926758766174, -0.08711579442024231, -0.02539973519742489, -0.22824768722057343, -0.006061776075512171, -0.12353931367397308, -0.10823260247707367, 0.02133508212864399, -0.08635701984167099, 0.2426542341709137, -0.03929685428738594, 0.2905779778957367, 0.05870852246880531, 0.016719212755560875, -0.05597703903913498, -0.04863499477505684, -0.013839418068528175, 0.011318918317556381, -0.02408709190785885, -0.11085085570812225, 0.06015242263674736, -0.15850839018821716, -0.1601089984178543, 0.013221514411270618, 0.15151913464069366, 0.028971007093787193, 0.0479690283536911, 0.017658419907093048, 0.013314219191670418, 0.06815572828054428, -0.26864302158355713, 0.14325252175331116, -0.04257184639573097, 0.005892634391784668, -0.0035824161022901535, -0.08594960719347, -0.04206680506467819, 0.13656356930732727, -0.07664429396390915, -0.05312710627913475, -0.10084488987922668, 0.08383119851350784, -0.05372852459549904, 0.10720496624708176, 0.0778050646185875, 0.01495029591023922, -0.1446235477924347, -0.10419350862503052, 0.04700547829270363, 0.04370959848165512, -0.1719193458557129, -0.21714890003204346, 0.13067179918289185], "changes": {"1wk": -0.6968634747042031, "1mo": -2.439022161464711}}, {"text": "Dogwood Therapeutics Announces Third Quarter 2024 Financial Results Dogwood Therapeutics, Inc. Thu, Nov 7, 2024, 3:05 PM 7 min read In This Article: DWTX +13.53% Dogwood Therapeutics, Inc. - Dogwood Therapeutics, Inc. (Nasdaq: \u201cDWTX\u201d) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the \u201cCombination\u201d) - - Expanded pipeline with multiple programs in large markets with high unmet need - - Strategic financing results in combined working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron \u00ae development through 2025 - - Top-line results from Long-COVID Phase 2a study expected in mid-November 2024 - - NaV 1.7 inhibition pain treatment, Halneuron \u00ae , Phase 2b study for chemotherapy-induced neuropathic pain expected interim readout 2H 2025 - ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the \u201cCompany\u201d), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. \u201cThe formation of Dogwood Therapeutics last month represents a transformational expansion of our pipeline with the addition of Halneuron \u00ae , a non-opioid, novel NaV 1.7 modulator to treat neuropathic pain associated with chemotherapy, purposefully complementing our promising development assets IMC-1 and IMC-2,\u201d said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. \u201cThe concurrent strategic financing to be provided by an affiliate of CK Life Sciences Int\u2019l., (Holdings) Inc. (\u201cCKLS\u201d), former owner of Pharmagesic (Holdings) Inc., provides us with operating capital through 2025. We see this as a win-win for legacy Virios shareholders and CKLS, with both short-term and medium-term value creation opportunities associated with forthcoming data from the Bateman-Horne Center (\u201cBHC\u201d) managed IMC-2 Phase 2 Long-COVID trial, and the Halneuron \u00ae Phase 2b interim data projected for the second half of next year.\u201d Key Highlights Dogwood\u2019s expanded pipeline includes three late-stage assets: Halneuron \u00ae , currently in Phase 2b development for chemotherapy-induced neuropathic pain (\u201cCINP\u201d); IMC-1, poised for Phase 3 development as a treatment for fibromyalgia (\u201cFM\u201d); and IMC-2, currently in Phase 2 development to treat Long-COVID (\u201cLC\u201d) sequelae. In connection with the Combination, the Company announced that it raised $19.5 million in committed debt financing by an affiliate of CKLS in two tranches with $16.5 million funded as of October 7, 2024 and an additional $3.0 million to be funded in 1Q 2025, subject to certain conditions. This financing is expected to fund research and operations through several key milestones, including the release of results from the Halneuron \u00ae Phase 2b interim analysis assessment expected in 2H 2025. Top-line results from the ongoing BHC IMC-2 LC Phase 2a study, assessing two doses of the combination of valacyclovir + celecoxib versus placebo, are expected by mid-November 2024. Story Continues Dogwood Therapeutics Proprietary Pipeline Includes: Halneuron \u00ae is in Phase 2b development as a non-opioid, NaV 1.7 inhibitor to treat the neuropathic pain associated with chemotherapy treatment. Halneuron \u00ae has been granted fast track designation from the Food and Drug Administration (\u201cFDA\u201d) for the treatment of CINP. Next milestone : Interim data from the ongoing Phase 2b CINP study are expected in 2H 2025. IMC-2 (valacyclovir + celecoxib) is in Phase 2a development as a combination antiviral treatment for LC. Next milestone : Topline data from an investigator led, double blind controlled proof of concept study, assessing two doses of IMC-2 vs placebo, are expected in mid-November 2024. IMC-1 (famciclovir + celecoxib) is ready for Phase 3 development as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA for the treatment of FM. Dogwood is exploring partnerships for IMC-1 to execute the Phase 3 FM program agreed upon by the FDA. Third Quarter 2024 Financial Results Research and development expenses increased by $0.2 million for the third quarter of 2024 compared to the third quarter of 2023. The quarter-over-quarter change was primarily due to increases in expenses associated with the grant to BHC for the second proof-of-concept study in LC of $0.3 million offset by a decrease in regulatory expenses of $0.1 million. General and administrative expenses increased by $0.9 million for the third quarter of 2024 compared to the third quarter of 2023. The quarter-over-quarter change was primarily due to higher legal and professional fees related to the business combination in October 2024 of $1.0 million offset by lower insurance expenses associated with being a public company of $0.1 million. Net loss for the third quarter of 2024 was $2.3 million, or $2.05 basic and diluted net loss per share, compared to a net loss of $1.2 million, or $1.62 basic and diluted net loss per share for the third quarter of 2023 (as adjusted to reflect the reverse stock split implemented on October 9, 2024). The Company estimates that its current cash of $2.0 million at September 30, 2024 along with the $16.5 million in loan proceeds received on October 7, 2024 is not sufficient to fund operating expenses and capital requirements for at least the next 12 months.\u00a0\u00a0 The Company will need to secure the additional $3.0 million of loan proceeds available to us under the terms of the loan agreement in February 2025 to continue to fund our operations through 2025. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on lead development candidate, Halneuron \u00ae which is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain. Halneuron \u00ae treatment has demonstrated pain reduction of both general cancer related pain and CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the treatment of illnesses believed to be related to reactivation of previously dormant herpes viruses, including FM and LC. Top-line data from an ongoing IMC-2 Phase 2 LC study are expected in mid-November 2024. IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. For more information, please visit www.dwtx.com. Follow Dogwood Therapeutics Email Alerts: https://ir.dwtx.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/dogwoodther/ Twitter: https://twitter.com/dogwoodther Facebook: https://www.facebook.com/dogwoodther Forward-Looking Statements Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \"will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood\u2019s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company\u2019s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Contact: IR@dwtx.com DOGWOOD THERAPEUTICS Selected Financial Data (unaudited) Condensed Statements of Operations Data Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ \u2014 $ \u2014 $ \u2014 $ \u2014 Operating expenses: Research and development 535,162 374,200 1,214,964 1,429,757 General and administrative 1,766,010 900,089 3,470,133 2,879,036 Total operating expenses 2,301,172 1,274,289 4,685,097 4,308,793 Loss from operations (2,301,172 ) (1,274,289 ) (4,685,097 ) (4,308,793 ) Other Income: Interest income 20,488 39,215 63,245 115,951 Total Other income 20,488 39,215 63,245 115,951 Net loss $ (2,280,684 ) $ (1,235,074 ) $ (4,621,852 ) $ (4,192,842 ) Net loss per share of common stock \u2014 basic and diluted, as adjusted $ (2.05 ) $ (1.62 ) $ (4.95 ) $ (5.63 ) Weighted average shares outstanding \u2014 basic and diluted, as adjusted 1,110,317 763,750 932,872 774,586 Condensed Balance Sheet Data September 30, December 31, 2024 2023 Cash $ 2,039,819 $ 3,316,946 Total assets 2,283,249 4,165,442 Total liabilities 1,333,818 358,548 Total stockholders\u2019 equity 949,431 3,806,894 Source: Dogwood Therapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-11-07T12:05:00+00:00", "sentiment": {"score": 0.7509531467221677, "confidence": 0.7583908438682556, "probabilities": {"positive": 0.7583908438682556, "negative": 0.007437697146087885, "neutral": 0.23417143523693085}}, "embedding": [-0.08244169503450394, -0.22863167524337769, 0.053210433572530746, 0.009434438310563564, -0.0887083187699318, -0.10949119925498962, -0.21584120392799377, 0.1292528510093689, 0.24535971879959106, 0.08793101459741592, -0.08992286026477814, 0.09074333310127258, 0.035971734672784805, 0.05369146168231964, -0.05984541028738022, 0.08183524012565613, 0.042117178440093994, 0.03385128453373909, -0.04032085835933685, 0.1486932635307312, 0.023147806525230408, 0.0020892308093607426, 0.014954129233956337, 0.018257204443216324, -0.033375103026628494, 0.10349155217409134, -0.058284975588321686, -0.04492725431919098, -0.1097523495554924, -0.03844531625509262, 0.14611056447029114, 0.15312853455543518, 0.0091913603246212, -0.061845965683460236, 0.04121808707714081, 0.03472808375954628, -0.15995800495147705, -0.04064308851957321, 0.0003246599808335304, -0.026041356846690178, -0.0412091389298439, 0.019523942843079567, -0.05467034876346588, 0.038635123521089554, 0.07711607217788696, -0.19647280871868134, -0.10261251032352448, -0.06053467094898224, -0.010910138487815857, 0.20312732458114624, -0.06800775974988937, -0.12478849291801453, 0.04306633770465851, 0.09369046986103058, -0.0828755721449852, 0.02960016205906868, -0.2526639997959137, -0.06679035723209381, 0.002290236996486783, 0.04734687879681587, 0.0592210590839386, 0.04807166010141373, 0.06735378503799438, -0.008004214614629745, 0.12860962748527527, 0.130330890417099, -0.037625495344400406, -0.0533876046538353, -0.04180204123258591, -0.11449340730905533, 0.031295813620090485, -0.09670265763998032, -0.0005308482795953751, 0.0484187938272953, 0.02759057655930519, 0.059017810970544815, 0.1778341680765152, 0.11945082247257233, 0.19675523042678833, -0.12633778154850006, 0.010241133160889149, 0.09903757274150848, 0.15173110365867615, 0.10080491006374359, -0.040390223264694214, 0.0062518129125237465, 0.08795638382434845, 0.23017844557762146, 0.0030909786000847816, -0.0005176104605197906, 0.07861541211605072, -0.06406310945749283, -0.03130166232585907, 0.0458216592669487, -0.03626835346221924, -0.036139920353889465, -0.17992019653320312, 0.07912895828485489, 0.024501090869307518, 0.005598798394203186, 0.004864352289587259, 0.008634215220808983, -0.10151505470275879, -0.23169128596782684, 0.06191881746053696, -0.10132089257240295, 0.09900638461112976, 0.03223209083080292, 0.07050445675849915, -0.03261769935488701, -0.10783930122852325, 0.020367106422781944, -0.09534931927919388, 0.04441734403371811, 0.027184810489416122, 0.1402558982372284, -0.016935434192419052, 0.025555886328220367, 0.23980560898780823, -0.05989384278655052, 0.08413639664649963, 0.003353527747094631, -0.048064224421978, -0.05332525819540024, -0.024943577125668526, 0.06059989705681801, -0.14677530527114868, 7.82084162656106e-33, -0.06257998943328857, -0.03232519328594208, 0.0843571126461029, -0.007726652547717094, -0.06263808906078339, -0.0631692185997963, 0.06787687540054321, 0.06159898266196251, -0.22351190447807312, -0.12833090126514435, -0.18489812314510345, 0.08426657319068909, 0.04599941521883011, 0.033609967678785324, -0.044232990592718124, -0.18239101767539978, -0.0011056708171963692, -0.013043859973549843, 0.11747655272483826, -0.04407421126961708, 0.07896317541599274, 0.07458572834730148, -0.0011647968785837293, 0.1254306584596634, -0.05289866775274277, -0.00584412133321166, -0.05826183035969734, 0.0814511850476265, 0.10354243218898773, 0.024420689791440964, -0.14097283780574799, -0.05344129726290703, 0.04349946230649948, -0.13611379265785217, -0.10530067980289459, 0.022808518260717392, -0.1101706251502037, -0.08949394524097443, -0.06618654727935791, 0.09383565187454224, 0.03338439390063286, 0.09800426661968231, -0.16296397149562836, -0.10367676615715027, 0.04172685742378235, -0.047104254364967346, -0.14318965375423431, 0.01048728171736002, -0.04333418980240822, -0.1349901407957077, -0.06371559202671051, 0.14490482211112976, 0.056521620601415634, -0.06791149079799652, -0.053484462201595306, 0.01073240302503109, -0.036069706082344055, -0.014533007517457008, 0.10033930093050003, 0.14926409721374512, -0.031197452917695045, -0.040898215025663376, -0.016296209767460823, 0.02104239910840988, -0.05445591360330582, 0.17624369263648987, -0.007330453023314476, -0.009117047302424908, -0.20391207933425903, 0.09526097774505615, -0.026363326236605644, -0.03156115114688873, 0.10162882506847382, 0.011733990162611008, 0.1281941533088684, -0.11678127199411392, 0.0536268875002861, 0.024897657334804535, -0.018865151330828667, 0.027246570214629173, -0.0197179913520813, 0.007778766565024853, -0.0684119462966919, 0.22426745295524597, 0.05094797536730766, -0.12063497304916382, -0.03890495374798775, -0.01857839897274971, -0.13602939248085022, -0.07693906873464584, 0.0021360539831221104, -0.09897537529468536, -0.05327501893043518, 0.17671260237693787, 0.10634811222553253, -9.263802084497697e-33, -0.039339035749435425, -0.0009825583547353745, -0.053035203367471695, -0.0698186606168747, -0.04606211930513382, 0.18117105960845947, 0.016210759058594704, -0.16176201403141022, 0.063315749168396, -0.04841594398021698, 0.1888972371816635, 0.06656473875045776, -0.12367593497037888, 0.02366003766655922, -0.15122798085212708, -0.000910523347556591, -0.021703213453292847, -0.008861501701176167, -0.02557416446506977, -0.03231044113636017, 0.07932530343532562, 0.26653891801834106, -0.05374326929450035, 0.10364709049463272, 0.03384757786989212, 0.0959739089012146, 0.1273345947265625, 0.03102392889559269, 0.04653433710336685, 0.0803247019648552, -0.043226685374975204, -1.2980308383703232e-07, -0.18332600593566895, -0.03154687210917473, -0.032602712512016296, 0.09021459519863129, 0.05869932845234871, -0.21987378597259521, -0.13963598012924194, -0.09029865264892578, 0.07729832828044891, -0.03857716917991638, -0.008015505969524384, 0.04591071233153343, 0.09031505882740021, 0.05635036528110504, 0.09032338857650757, -0.07282993942499161, 0.10788032412528992, 0.0751848816871643, -0.03219630941748619, 0.03833720460534096, -0.02128114178776741, 0.06173747777938843, -0.04563041776418686, 0.03443804755806923, -0.024656204506754875, -0.015200572088360786, 0.05454399436712265, -0.09079377353191376, -0.11384422332048416, 0.10076827555894852, 0.08775336295366287, -0.09021517634391785, 0.02461748756468296, 0.03287399560213089, 0.015286058187484741, 0.051113881170749664, 0.05780051648616791, -0.19353610277175903, -0.06842202693223953, 0.051883403211832047, -0.050538819283246994, -0.034970592707395554, 0.007244693115353584, 0.17165827751159668, 0.04463165998458862, -0.23185956478118896, -0.1235247328877449, -0.03999266028404236, -0.031211601570248604, -0.0728677362203598, 0.011170091107487679, 0.11295737326145172, 0.0176541805267334, 0.029925178736448288, 0.04825294017791748, 0.08375705033540726, -0.04187847673892975, 0.029382813721895218, -0.006438759155571461, -0.10663439333438873, -0.07082736492156982, 0.16573581099510193, -0.020923592150211334, -1.003554714884558e-07, 0.03729372099041939, 0.018099535256624222, -0.002988942200317979, -0.04351789131760597, 0.03743448853492737, 0.029012709856033325, -0.05295997112989426, 0.019911346957087517, -0.1163487583398819, 0.17841829359531403, 0.08673465996980667, 0.10231315344572067, -0.11711590737104416, 0.01045176200568676, -0.13557767868041992, 0.11499097943305969, -0.05296111851930618, 0.0796048641204834, 0.03802324831485748, -0.036688417196273804, -0.14917291700839996, -0.010731235146522522, 0.0989527702331543, -0.10578173398971558, 0.07648303359746933, -0.181422621011734, -0.017391908913850784, 0.03212863206863403, -0.015573736280202866, -0.06995932757854462, -0.007569595240056515, 0.08707144856452942, 0.017966507002711296, -0.04585222899913788, -0.05021858960390091, -0.10483460128307343, 0.042143240571022034, 0.10029265284538269, 0.028640788048505783, 0.13333910703659058, -0.03557330369949341, 0.07474212348461151, -0.09285089373588562, 0.04318995028734207, 0.011235320940613747, -0.03379831463098526, -0.07618438452482224, 0.03738720342516899, 0.08034002780914307, -0.11335104703903198, -0.038526542484760284, -0.0036995159462094307, -0.059565942734479904, -0.04511028155684471, -0.09942270070314407, 0.1815694272518158, -0.12191260606050491, -0.12967301905155182, 0.03053276054561138, -0.15621502697467804, 0.08169328421354294, -0.22269979119300842, 0.07401067018508911, 0.0348261334002018], "changes": {"1wk": -33.258423462703725, "1mo": -46.74157332266361}}, {"text": "Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ... GuruFocus News Fri, Nov 8, 2024, 10:15 AM 4 min read In This Article: DWTX +13.53% Cash: $2 million as of September 30, 2024. Strategic Financing: $19.5 million, with $16.5 million received and an additional $3 million expected in February 2025. Working Capital: Approximately $23 million, including combined cash of the entities at the time of the business combination. Phase Two Study - Cancer Related Pain: Statistically significant pain reduction in a study with 165 patients. Phase Two Study - Chemotherapy Induced Neuropathic Pain: 125 patients, higher doses of Hal Neuron showed greater pain reduction. Long COVID Proof of Concept Study: 22 patients treated, significant improvement in fatigue and other symptoms compared to 17 matched controls. Long COVID Phase Two Study: 45 patients enrolled, results expected shortly. Warning! GuruFocus has detected 1 Warning Sign with DWTX. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Dogwood Therapeutics Inc ( NASDAQ:DWTX ) announced a strategic business combination with Pharmagest Holding Incorporated, resulting in a significant expansion of their pipeline. The company secured a $19.5 million strategic financing, with $16.5 million already received and an additional $3 million expected in February 2025, providing approximately $23 million in working capital. The expanded pipeline includes Hal Neuron, a NAV 1.7 modulator, which has shown promising results in reducing cancer-related pain and chemotherapy-induced neuropathic pain. Dogwood Therapeutics Inc ( NASDAQ:DWTX ) has a strong management team with extensive experience in developing and commercializing blockbuster drugs. The company is poised to release top-line results from their long COVID phase two study and has a clear path for future development milestones. Negative Points Dogwood Therapeutics Inc ( NASDAQ:DWTX ) reported a cash balance of only $2 million as of September 30, 2024, prior to the strategic financing. The company is reliant on future financing and successful milestone achievements to sustain operations beyond 2025. There are no FDA-approved treatments for chemotherapy-induced neuropathic pain, indicating a challenging regulatory pathway. The long COVID study results are still pending, and the company faces uncertainty regarding the efficacy of their treatment in this area. The company has yet to finalize the design and regulatory approval for the phase two B trial of Hal Neuron, which could delay progress. Q & A Highlights Q : Can you discuss the durability of response for Hal Neuron and any dose-response relationship observed? A : (R. Michael Gendreau, Chief Medical Officer) In the cancer-related pain study, the average response duration was 57 days for Hal Neuron compared to 10.5 days for placebo among responders. This was from a single cycle of four days of injections. We observed a dose-response relationship in the chemotherapy-induced neuropathic pain study, with the best results at the highest dose, which we are taking forward into the phase two B study. Story Continues Q : Are there any respiratory-related tolerability issues with Hal Neuron, and how does once-a-day dosing compare to twice-a-day? A : (R. Michael Gendreau, Chief Medical Officer) We did not observe any respiratory adverse events. Once-a-day dosing showed a better tolerability profile compared to twice-a-day, with no meaningful change in efficacy, making it the preferred choice. Q : What are the details and steps required for the phase two B trial for Hal Neuron? A : (R. Michael Gendreau, Chief Medical Officer) The phase two B trial will use a high dose once-a-day regimen over eight days, with a primary endpoint at week four. It will be a 1:1 randomization against placebo, with an interim analysis planned for the second half of 2025. The trial design is consistent with FDA expectations, focusing on pain reduction over time. Q : Are there any conditions to receive the second tranche of funding in February 2025? A : (Gregory Duncan, CEO) There are no material obligations to meet for the additional $3 million, as long as we maintain consistent listing standards and other public entity requirements. CKLS is committed to the asset and its development. Q : Will the FDA require data on opioid reduction in your trials? A : (R. Michael Gendreau, Chief Medical Officer) While the FDA may be interested in rescue medication reduction, we do not plan to pursue an opioid-sparing claim. The trial will aim to keep ancillary medications constant, using non-opioid rescue options to avoid complicating the results. For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-11-08T07:15:36+00:00", "sentiment": {"score": 0.6580151934176683, "confidence": 0.6730256676673889, "probabilities": {"positive": 0.6730256676673889, "negative": 0.015010474249720573, "neutral": 0.311963826417923}}, "embedding": [-0.06181750446557999, -0.19505052268505096, 0.07296343147754669, 0.013418021611869335, -0.14919346570968628, -0.1020098328590393, -0.0829559862613678, 0.16840505599975586, 0.24872519075870514, 0.04880065470933914, 0.011403661221265793, 0.10920736193656921, 0.06754717230796814, 0.059808723628520966, -0.052885085344314575, 0.04327601194381714, 0.09668022394180298, -0.009771306067705154, -0.012921664863824844, 0.0857488363981247, -0.06449241191148758, 0.011167803779244423, -0.001771785318851471, 0.019797619432210922, -0.04272473230957985, 0.001770982053130865, -0.045726925134658813, -0.051344133913517, -0.0911080464720726, -0.04304956644773483, 0.1657637357711792, 0.10599781572818756, -0.03127175569534302, -0.06259843707084656, 0.006941351108253002, 0.02031048759818077, -0.18600289523601532, -0.0012371258344501257, -0.023478828370571136, -0.007680944632738829, -0.021174823865294456, 0.041268981993198395, -0.1010078489780426, 0.02688710391521454, 0.11238410323858261, -0.17785649001598358, -0.11569859087467194, -0.02456115372478962, 0.056776586920022964, 0.12025542557239532, -0.038502637296915054, -0.10784873366355896, 0.09606128931045532, 0.035055458545684814, -0.08994117379188538, -0.008168423548340797, -0.1912328451871872, -0.08343175053596497, -0.02335958182811737, 0.06019136682152748, 0.0640239268541336, 0.04538126289844513, 0.08983081579208374, -0.02698272466659546, 0.18067485094070435, 0.18803274631500244, -0.08007515221834183, -0.10515430569648743, -0.026806572452187538, -0.06222819536924362, -0.010542438365519047, -0.06915002316236496, 0.041951827704906464, -0.0707634687423706, -0.02941454015672207, 0.0466519296169281, 0.09009918570518494, 0.09682200849056244, 0.19111832976341248, -0.07618257403373718, -0.004546072334051132, 0.07985511422157288, 0.1394377052783966, 0.1758241504430771, -0.004738705698400736, -0.03839821368455887, 0.15373069047927856, 0.2181401550769806, -0.01540621928870678, -0.0005463241832330823, 0.06671076267957687, -0.035635098814964294, -0.11193571239709854, 0.07931192219257355, -0.09387592226266861, -0.07186266034841537, -0.196891188621521, 0.06489339470863342, -0.07098118960857391, 0.0031408630311489105, 0.0553739070892334, 0.055673275142908096, -0.09504564106464386, -0.17788881063461304, 0.038756467401981354, -0.08614808320999146, 0.0587339922785759, 0.014325873926281929, 0.015039402060210705, -0.004924898035824299, -0.12787045538425446, 0.012584028765559196, -0.12109532952308655, 0.03672890365123749, -0.024272598326206207, 0.1708739995956421, -0.02889399044215679, 0.04321911185979843, 0.16374364495277405, -0.09650032222270966, 0.1065201684832573, -0.03827777877449989, -0.080529123544693, -0.04143844544887543, -0.005237424746155739, 0.08017546683549881, -0.12394587695598602, 1.263076467608622e-32, -0.03258075565099716, 0.029726602137088776, 0.057309143245220184, -0.04647215083241463, 0.0007470604032278061, -0.0013801541645079851, -0.022755667567253113, 0.08436258137226105, -0.18665795028209686, -0.09108845144510269, -0.1733035445213318, 0.0864633321762085, 0.04610738903284073, 0.024971770122647285, -0.07231888920068741, -0.12354740500450134, -0.03378760442137718, -0.04771432280540466, 0.04167480766773224, -0.013248736038804054, 0.0514785461127758, 0.022515276446938515, -0.04449959471821785, 0.07325173914432526, -0.06996322423219681, 0.008762214332818985, -0.14123296737670898, 0.08030581474304199, 0.05777107924222946, -0.019815469160676003, -0.16899779438972473, -0.11137572675943375, 0.08972067385911942, -0.06857456266880035, -0.15182596445083618, 0.025043979287147522, -0.08275531232357025, -0.15621700882911682, -0.036049384623765945, 0.06317871809005737, -0.0010278900153934956, 0.16380463540554047, -0.04846383258700371, -0.0902174562215805, 0.03757987543940544, 0.012189790606498718, -0.08160661160945892, -0.042858269065618515, -0.07179766893386841, -0.0566842295229435, -0.09737537056207657, 0.17832916975021362, 0.06353519856929779, -0.08167167007923126, -0.05482140928506851, -0.007667238358408213, -0.013926975429058075, 0.06347960233688354, 0.15329685807228088, 0.1956554353237152, -0.0018949555233120918, -0.1128820851445198, -0.0397055484354496, -0.03593406081199646, -0.04601115733385086, 0.19110602140426636, 0.05335554480552673, -0.01495872437953949, -0.16079562902450562, 0.09142764657735825, -0.04859547317028046, 0.09386657178401947, 0.09867358952760696, -0.0035184351727366447, 0.04681200161576271, -0.07734010368585587, 0.051890164613723755, 0.01730894297361374, -0.0203092060983181, 0.011355115100741386, -0.024528928101062775, -0.07849912345409393, -0.04465081915259361, 0.20270368456840515, 0.12663349509239197, -0.0811835303902626, -0.0924038365483284, 0.02089248225092888, -0.13733471930027008, -0.0789661779999733, -8.905353024601936e-05, -0.03648564964532852, -0.030503790825605392, 0.15651878714561462, 0.13414883613586426, -1.2197017546208367e-32, -0.1143740564584732, 0.07440216839313507, -0.04854334890842438, -0.0734623447060585, -0.00422312319278717, 0.15207920968532562, -0.05415754020214081, -0.061834678053855896, 0.05416949465870857, 0.010953245684504509, 0.09241336584091187, 0.11073726415634155, -0.10934191942214966, 0.0387391522526741, -0.18540725111961365, 0.05929230898618698, -0.08923092484474182, 0.01124301552772522, -0.04639514908194542, -0.10521501302719116, 0.037142861634492874, 0.39426469802856445, -0.01936536282300949, 0.08995310962200165, 0.060576871037483215, 0.146760955452919, 0.10239158570766449, 0.013926596380770206, -0.028950894251465797, 0.01037568412721157, 0.017637906596064568, 0.04832593351602554, -0.15100529789924622, -0.007319924887269735, -0.05720754340291023, 0.04945496469736099, 0.06176763400435448, -0.13432812690734863, -0.07310647517442703, -0.06732223182916641, 0.1404353827238083, -0.012359729036688805, 0.015946073457598686, -0.008701884187757969, 0.041027896106243134, 0.04225669428706169, 0.0461658351123333, -0.13469544053077698, 0.1535300612449646, 0.1922772228717804, -0.06777728348970413, 0.050361283123493195, 9.73318237811327e-05, 0.0986885130405426, -0.03626679256558418, 0.021277789026498795, 0.04396595433354378, -0.0470326691865921, 0.014135066419839859, -0.013038723729550838, -0.09714344888925552, 0.11960040777921677, 0.08041618019342422, -0.04238347336649895, 0.0019343271851539612, 0.0020385663956403732, 0.03850019350647926, 0.06937146186828613, 0.10321084409952164, -0.17552495002746582, -0.18489429354667664, 0.11652743816375732, -0.06638500094413757, -0.05372542142868042, -0.02001187950372696, 0.17054420709609985, 0.0182094294577837, -0.2003559023141861, -0.039361126720905304, -0.039537448436021805, -0.021030254662036896, -0.11188114434480667, 0.06391382962465286, 0.06615528464317322, 0.022638391703367233, 0.024136008694767952, 0.007933210581541061, 0.13493117690086365, -0.07003965228796005, 0.05009424686431885, 0.030139779672026634, -0.03516705706715584, -0.0588311105966568, 0.10386405140161514, -0.0006236061453819275, -1.0017227225489478e-07, -0.017790282145142555, 0.028089413419365883, -0.022084662690758705, -0.07778243720531464, 0.05334737151861191, -0.01751924306154251, -0.06531615555286407, 0.0603877417743206, -0.11757029592990875, 0.18271520733833313, 0.11783021688461304, 0.04590008407831192, -0.23849982023239136, 0.03702773153781891, -0.17413294315338135, 0.12372177839279175, -0.0492793433368206, 0.07290653884410858, 0.012777124531567097, -0.03448278456926346, -0.10891664028167725, -0.03224159777164459, 0.06361564993858337, -0.06759587675333023, 0.04832257702946663, -0.16231684386730194, 0.06587465852499008, 0.12391413748264313, -0.038490377366542816, -0.10256273299455643, -0.041665032505989075, 0.042597949504852295, 0.015118543989956379, -0.017971355468034744, -0.07803769409656525, -0.11960439383983612, 0.04481097310781479, 0.09525466710329056, 0.02617107704281807, 0.16098660230636597, -0.012838120572268963, -0.0023995782248675823, -0.08366233110427856, 0.020360758528113365, -0.003234580624848604, 0.0009683079551905394, -0.08031265437602997, -0.019037574529647827, 0.11632969975471497, -0.01747121289372444, 0.006648593116551638, -0.001862778328359127, 0.02113291248679161, -0.07145318388938904, -0.15191605687141418, 0.15146321058273315, -0.11907346546649933, -0.004539720714092255, 0.017446570098400116, -0.08547253161668777, 0.057048358023166656, -0.30761638283729553, 0.0784732922911644, 0.0010231928899884224], "changes": {"1wk": -25.58139754089544, "1mo": -44.88372603643879}}, {"text": "Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study Dogwood Therapeutics, Inc. Mon, Nov 18, 2024, 4:45 PM 6 min read In This Article: DWTX +13.53% Dogwood Therapeutics, Inc. - IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo \u2013 - Top-line results from the Bateman Horne Center\u2019s Long-COVID study provide key insights into final design of Dogwood\u2019s planned Phase 2 study, projected to enroll approximately 200 participants - ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the \u201cCompany\u201d), a development-stage biotechnology company advancing new medicines to treat pain and fatigue-related disorders, today announced top line data from the recently completed BHC IMC-2 Long-COVID study. The study was conducted via an investigator-initiated, investigational research grant provided to the Bateman Horne Center (\u201cBHC\u201d). The study demonstrated that the low dose combination antiviral therapy IMC-2 treated patient cohort (valacyclovir 750 mg + celecoxib dosed 200 mg twice daily) exhibited clinically meaningful reductions in Long-COVID associated fatigue and sleep disturbance, as compared with the placebo treated cohort. The high dose IMC-2 treated cohort (valacyclovir 1500 mg + celecoxib 200 mg dosed twice daily) did not exhibit clinically meaningful differences versus placebo, believed to be related to higher levels of gastrointestinal (GI) adverse events associated with the higher dose regimen. \u201cTo date, there are no FDA approved medicines to treat Long-COVID symptoms,\u201d said Lucinda Bateman, MD, Founder and Chief Medical Officer of the Bateman Horne Center and the study\u2019s principal investigator. \u201cThis trial provides evidence that IMC-2 has the potential to improve fatigue and sleep symptoms associated with Long-COVID illness on a scale not previously observed in Long-COVID research. I believe this finding warrants further investigation of IMC-2 in larger scale, multi-center Long-COVID studies.\u201d \u201cThe primary goals of this trial were to determine the IMC-2 treatment effect size versus placebo and the associated patient sample size to design our planned IMC-2 Phase 2 Long-COVID study in a manner that maximizes probability of success,\u201d said R. Michael Gendreau, MD, Chief Medical Officer of Dogwood Therapeutics, Inc. \u201cIMC-2 demonstrated a robust reduction in fatigue, the primary endpoint agreed with the Food & Drug Administration to advance IMC-2 into Phase 2 development. We look forward to finalizing these plans and providing further information on next steps in the coming months.\u201d IMC-2 Long-COVID Development Program Summary: BHC Study 201: Investigator-initiated, open-label, matched control study assessing IMC-2 treatment versus patients matched by age, duration of effect, vaccination status and gender. In this study, completed in 2023, the combination of valacyclovir and celecoxib exhibited statistically significant reductions in Long-COVID related fatigue, orthostatic intolerance, pain and anxiety, while improving overall patient health. The dosage used in this study was valacyclovir 1500 mg + celecoxib 200 mg dosed twice daily. Story Continues BHC Study 202: This recently completed study was designed as an investigator-initiated, double-blinded, placebo controlled follow-on study to BHC 201. While not statistically significant given the small sample size recruited for this trial (14-15 per group), the study demonstrated that the low dose combination antiviral therapy IMC-2 exhibited clinically meaningful improvements in fatigue and sleep disruption as compared to placebo treated patients. Overall, the IMC-2 adverse event profile was favorable in this study. The high dose IMC-2 treatment (valacyclovir 1500 mg + celecoxib 200 mg dosed twice daily) resulted in more GI related adverse events compared to the low dose and placebo cohorts. Additional Assets in Dogwood Therapeutics Proprietary Pipeline: Halneuron \u00ae is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor to treat the neuropathic pain resultant from chemotherapy treatment. Halneuron \u00ae has been granted Fast Track Designation from the FDA for the treatment of Chemotherapy-Induced Neuropathic Pain (CINP). Next milestone : Interim data from the ongoing Phase 2 CINP study are expected in the second half of 2025. IMC-1 (famciclovir + celecoxib) is Phase 3 development ready as a combination antiviral treatment for fibromyalgia (FM). IMC-1 has been granted fast track designation by the FDA as a treatment for FM. Next milestone : Dogwood is exploring partnerships for IMC-1 to execute the Phase 3 FM program as agreed with the FDA. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on lead development candidate, Halneuron \u00ae which is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain. Halneuron \u00ae treatment has demonstrated pain reduction of both general cancer related pain and CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the treatment of illnesses believed to be related to reactivation of previously dormant herpes viruses, including FM and LC. IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. For more information, please visit www.dwtx.com. Follow Dogwood Therapeutics Email Alerts: https://ir.dwtx.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/dogwoodther/ Twitter: https://twitter.com/dogwoodther Facebook: https://www.facebook.com/dogwoodther Forward-Looking Statements Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \"will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood\u2019s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company\u2019s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Contact: IR@dwtx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-11-18T13:45:00+00:00", "sentiment": {"score": 0.7522163055837154, "confidence": 0.8111697435379028, "probabilities": {"positive": 0.8111697435379028, "negative": 0.05895343795418739, "neutral": 0.12987691164016724}}, "embedding": [0.02099299430847168, -0.14950621128082275, 0.001780843362212181, 0.1251530796289444, -0.02071668580174446, -0.030192218720912933, -0.14799027144908905, 0.23379652202129364, 0.18380433320999146, 0.004757257644087076, -0.1683400571346283, 0.07954905927181244, 0.12381500005722046, 0.07214715331792831, -0.022373730316758156, 0.06589654833078384, 0.16285616159439087, 0.11620338261127472, -0.013876345008611679, 0.06294119358062744, 0.0014400631189346313, -0.08667570352554321, 0.19353227317333221, 0.1589207649230957, -0.14735537767410278, 0.035919468849897385, -0.11674242466688156, -0.048928625881671906, -0.09402944147586823, -0.0009398637339472771, 0.11684160679578781, 0.20524971187114716, 0.08793879300355911, -0.05288909003138542, -0.012320246547460556, 0.014559182338416576, -0.03545253351330757, -0.0076388041488826275, -0.0987030416727066, -0.048233531415462494, -0.07196955382823944, 0.0621519573032856, 0.028218716382980347, -0.037695758044719696, -0.035769060254096985, -0.1563592404127121, -0.1815442442893982, -0.0792185366153717, -0.014770997688174248, 0.23021024465560913, -0.0551343634724617, -0.07319468259811401, -0.013498646207153797, 0.11469512432813644, -0.04405592381954193, -0.0551287904381752, -0.22771891951560974, 0.016286900267004967, 0.057955481112003326, 0.1045977920293808, -0.02324514277279377, 0.1380728930234909, 0.07368246465921402, 0.04296146705746651, 0.09524078667163849, 0.13475805521011353, -0.12945164740085602, -0.0568266436457634, 0.014918064698576927, -0.034693390130996704, -0.1450681984424591, -0.13429288566112518, -0.014492066577076912, -0.010228423401713371, -0.0605374351143837, 0.016059469431638718, 0.15142089128494263, 0.03689434379339218, 0.20901040732860565, -0.1587783396244049, -0.03580377995967865, 0.13450543582439423, 0.17915666103363037, 0.037184447050094604, -0.07526867091655731, -0.09339830279350281, 0.14761507511138916, 0.2381790429353714, -0.016079125925898552, 0.019174614921212196, 0.2696440815925598, -0.03015640377998352, -0.07735688984394073, 0.10448385775089264, 0.14159370958805084, -0.06692853569984436, -0.16262103617191315, 0.10092774778604507, -0.03156491741538048, -0.09105956554412842, -0.024289611726999283, -0.00924582127481699, -0.07002849876880646, -0.059271469712257385, -0.0025650905445218086, -0.07042662799358368, 0.08251678943634033, 0.029617823660373688, 0.03192208334803581, -0.04988426715135574, -0.044517286121845245, 0.0900963693857193, -0.050978321582078934, 0.04690863937139511, 0.032289694994688034, 0.2194022238254547, 0.04664255306124687, 0.07511403411626816, 0.16550377011299133, -0.05091184377670288, 0.14244402945041656, -0.07706087082624435, 0.11926242709159851, -0.2124655842781067, 0.019421782344579697, 0.05707376077771187, -0.028358636423945427, 1.0144491268341386e-32, -0.039462219923734665, 0.006508301943540573, 0.07511407881975174, 0.10197218507528305, -0.05805147811770439, 0.010364250279963017, 0.007442391477525234, 0.16068078577518463, -0.027092332020401955, -0.06742307543754578, -0.07157403975725174, 0.10544806718826294, 0.10385462641716003, 0.09692858904600143, -0.04261746257543564, -0.04750923812389374, -0.00570745300501585, -0.05914929136633873, -0.0008814232423901558, 0.05971879884600639, 0.04396091401576996, 0.01592293009161949, 0.12377869337797165, 0.15288028120994568, 0.005316117778420448, 0.010684953071177006, -0.0693020299077034, 0.10708002001047134, -0.07262280583381653, 0.009617570787668228, -0.09072618186473846, -0.08055206388235092, 0.07943218946456909, -0.06617951393127441, -0.13413570821285248, -0.013885464519262314, -0.015895649790763855, -0.08985041081905365, -0.007688818499445915, 0.1220853179693222, 0.03407096117734909, 0.06077089533209801, -0.03994729369878769, 0.005956219509243965, 0.0303510595113039, -0.08528704196214676, -0.15598371624946594, 0.015883944928646088, -0.11247777938842773, 0.03889520466327667, -0.0390811450779438, 0.05530139431357384, -0.06544627249240875, -0.1127130389213562, -0.07707437127828598, 0.08381177484989166, -0.016364991664886475, 0.05644030496478081, 0.0851794108748436, 0.1239306852221489, 0.041970524936914444, 0.07723947614431381, 0.004173529800027609, -0.004922967404127121, 0.03593127056956291, -0.015080459415912628, -0.0906573235988617, -0.04693426191806793, -0.26991721987724304, 0.038712576031684875, 0.017816292122006416, -0.06477605551481247, 0.08674149960279465, 0.10025723278522491, 0.13793125748634338, -0.17356567084789276, 0.017186656594276428, 0.07666163891553879, -0.10629000514745712, -0.10720387101173401, -0.10702066123485565, 0.0005114930681884289, -0.023386284708976746, 0.13639023900032043, 0.010473828762769699, -0.030843019485473633, -0.14276368916034698, 0.07133838534355164, -0.18162229657173157, -0.01795266568660736, -0.021103959530591965, -0.06472474336624146, 0.018349142745137215, 0.12321372330188751, 0.05877044424414635, -1.1303925427595564e-32, -0.08636950701475143, -0.059681542217731476, -0.10056732594966888, -0.10910153388977051, 0.005938954185694456, 0.19164693355560303, 0.05147537589073181, -0.17732113599777222, 0.12034639716148376, -0.10930812358856201, 0.18470263481140137, 0.052000559866428375, -0.1623518019914627, -0.0037634617183357477, -0.12884636223316193, -0.014453034847974777, -0.016406428068876266, 0.02932969108223915, -0.20179560780525208, 0.10008172690868378, 0.06265172362327576, 0.13136771321296692, -0.11895894259214401, -0.10270924866199493, 0.041133031249046326, 0.11833924055099487, 0.12922826409339905, -0.007093770429491997, 0.09934311360120773, 0.0028723105788230896, 0.0008511092164553702, 0.034250468015670776, -0.20162345468997955, -0.02953195944428444, 0.021026646718382835, 0.041403964161872864, 0.03405121713876724, -0.22523340582847595, -0.19236986339092255, -0.13586166501045227, 0.1086103767156601, 0.1054936945438385, -0.09499716758728027, -0.07840883731842041, 0.09823378920555115, 0.1061912402510643, 0.008146446198225021, -0.15153057873249054, 0.0895131528377533, 0.11534053087234497, -0.021772658452391624, -0.041432708501815796, -0.006521468050777912, 0.10932062566280365, -0.04879990965127945, -0.08058330416679382, -0.08298270404338837, -0.07141946256160736, -0.08964289724826813, -0.030727030709385872, -0.0022136270999908447, 0.13044513761997223, 0.051288049668073654, -0.07786248624324799, 0.15749961137771606, 0.05589413270354271, -0.01180861983448267, 0.008021458052098751, 0.1885380893945694, -0.21666701138019562, -0.09075900912284851, -0.16690021753311157, -0.11506623029708862, -0.0831860825419426, -0.08955755084753036, 0.19648772478103638, 0.024023599922657013, -0.14765334129333496, -0.041996221989393234, -0.14623549580574036, -0.01099404226988554, -0.23261350393295288, 0.03158695623278618, -0.028687557205557823, -0.058719854801893234, 0.01595607027411461, -0.06933214515447617, 0.011611657217144966, 0.0839097648859024, 0.0741983950138092, -0.07444378733634949, -0.0895078182220459, -0.09156043827533722, 0.008298054337501526, 0.10779452323913574, -1.0066959532650799e-07, 0.020128004252910614, -0.09396959841251373, -0.03125271946191788, -0.011206511408090591, 0.02539866231381893, 0.04278341680765152, -0.16958945989608765, 0.032608337700366974, -0.15240463614463806, 0.2356477826833725, 0.12702883780002594, 0.050200946629047394, 0.009182100184261799, -0.03579990938305855, -0.16513195633888245, 0.11877575516700745, -0.014000264927744865, 0.058509983122348785, 0.018344897776842117, 0.08778724819421768, -0.17227566242218018, -0.13435214757919312, -0.024073906242847443, -0.15931254625320435, 0.07400741428136826, -0.14977478981018066, 0.0673631951212883, 0.04867725819349289, -0.006875806488096714, -0.21131989359855652, -0.030295230448246002, 0.04784475639462471, -0.007691832259297371, -0.015954816713929176, 0.036274511367082596, -0.12031596153974533, 0.10576734691858292, 0.02594788745045662, 0.09171833842992783, 0.2391684502363205, -0.002165412064641714, 0.05245713144540787, -0.13590669631958008, 0.03048761561512947, 0.12660659849643707, 0.010333730839192867, -0.08613504469394684, -0.04851408675312996, -0.02436285838484764, -0.033288002014160156, -0.11419665068387985, 0.042922209948301315, 0.0017145397141575813, -0.04717223346233368, -0.12393179535865784, 0.17878441512584686, -0.0275914017111063, -0.06603078544139862, 0.13170231878757477, -0.21270538866519928, 0.021438755095005035, -0.11846017837524414, 0.03364025428891182, -0.005288826301693916], "changes": {"1wk": 37.837833483955876, "1mo": 26.486480216896467}}, {"text": "PREMIUM Top Premarket Decliners MT Newswires Mon, Nov 11, 2024, 3:49 PM In This Article: DWTX +13.53% VMAR -9.38% Top Premarket Decliners PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DWTX", "date": "2024-11-11T12:49:32+00:00", "sentiment": {"score": 0.028184283524751663, "confidence": 0.04384615644812584, "probabilities": {"positive": 0.04384615644812584, "negative": 0.015661872923374176, "neutral": 0.9404919743537903}}, "embedding": [-0.1839682012796402, -0.11678359657526016, 0.13134942948818207, 0.058116789907217026, 0.179513081908226, -0.038978461176157, -0.01203685998916626, 0.13199381530284882, 0.04535633325576782, -0.021091483533382416, -0.0012989739188924432, 0.11303063482046127, -0.032836899161338806, -0.04804714396595955, 0.07365486770868301, -0.10650701075792313, 0.16811108589172363, 0.022206993773579597, -0.034431710839271545, 0.07492325454950333, -0.21209870278835297, -0.026342345401644707, -0.009755528531968594, -0.08118594437837601, 0.19835226237773895, 0.004176425281912088, -0.15272434055805206, 0.128059521317482, 0.08658388257026672, -0.05253329873085022, -0.02509130723774433, 0.03892941400408745, 0.17387427389621735, 0.023601554334163666, -0.19106590747833252, -0.17187023162841797, -0.006527590099722147, -0.06934433430433273, -0.033099181950092316, 0.03892737999558449, 0.07413094490766525, -0.08234647661447525, -0.1148352399468422, -0.010439496487379074, -0.11702221632003784, -0.09648516029119492, -0.03773108497262001, 0.010332737118005753, -0.07669225335121155, 0.09687396138906479, 0.040031444281339645, -0.11012744903564453, 0.06279757618904114, -0.12349823862314224, -0.05117855593562126, -0.03241000697016716, -0.1090700700879097, -0.19496089220046997, 0.0019472992280498147, -0.09842714667320251, 0.014621853828430176, -0.06054657697677612, -0.07168183475732803, 0.011373954825103283, -0.0014355792663991451, 0.15061470866203308, 0.0933099091053009, 0.25047749280929565, 0.030873680487275124, -0.17034964263439178, -0.06033072993159294, 0.1388646811246872, -0.017187906429171562, 0.06342127919197083, -0.010017767548561096, 0.11590465158224106, 0.2381107360124588, -0.09967907518148422, 0.2300456166267395, -0.1901949644088745, 0.037529151886701584, 0.02404041402041912, 0.011081773787736893, 0.009591174311935902, 0.001490441500209272, -0.07424040138721466, 0.04317962005734444, -0.025861451402306557, 0.0073260837234556675, -0.1735655516386032, 0.11078929901123047, 0.03797389566898346, -0.10303162783384323, 0.08499646186828613, -0.08792950958013535, 0.007077943067997694, -0.13125155866146088, -0.15077926218509674, -0.15777312219142914, 0.12209561467170715, 0.0982857421040535, 0.1153433620929718, -0.135074183344841, 0.02683241106569767, -0.03159134089946747, -0.1868380457162857, -0.03650731220841408, 0.232123002409935, -0.01123855635523796, 0.0685797706246376, 0.0006494050030596554, 0.05729854106903076, 0.006657636258751154, -0.17624862492084503, -0.1886635422706604, 0.007093377411365509, -0.1253172904253006, 0.07906946539878845, 0.1482980102300644, -0.1029304638504982, 0.03659652918577194, 0.15416327118873596, -0.05440374091267586, 0.050894010812044144, -0.034756291657686234, -0.062480535358190536, -0.022762425243854523, 1.665837713335595e-32, -0.09143048524856567, 0.07584057748317719, 0.0558507926762104, -0.10112025588750839, 0.016660792753100395, 0.04568679258227348, -0.12476915121078491, -0.07808828353881836, -0.14781434834003448, -0.011640232987701893, -0.08768334984779358, 0.1608365923166275, -0.10053598880767822, 0.04206839203834534, 0.02325497753918171, -0.2619877755641937, 0.033746737986803055, 0.08361513167619705, 0.07812738418579102, -0.042305976152420044, 0.09863659739494324, -0.07342135906219482, -0.060035377740859985, -0.035280074924230576, -0.06313500553369522, 0.11121001094579697, 0.09563878923654556, 0.039867859333753586, 0.13437336683273315, 0.11576718837022781, -0.19145236909389496, -0.126156285405159, 0.07472870498895645, 0.05878245830535889, 0.0395108126103878, 0.20711910724639893, -0.09213737398386002, -0.09197542816400528, -0.06815195828676224, -0.1857038140296936, -0.1628691554069519, 0.0005290359258651733, -0.2950712740421295, -0.02983918972313404, -0.16500011086463928, 0.04098481312394142, 0.0261810515075922, -0.16520510613918304, 0.14706620573997498, -0.11232796311378479, -0.17152057588100433, 0.08989334106445312, -0.13894252479076385, -0.021643197163939476, -0.011211858130991459, 0.07473290711641312, 0.048993732780218124, -0.035103410482406616, 0.15477891266345978, -0.042168471962213516, 0.03082120604813099, 0.05756091699004173, 0.041048314422369, -0.0344318188726902, -0.077979676425457, 0.1721501499414444, 0.042899638414382935, -0.0904259979724884, -0.17357231676578522, 0.06244480982422829, 0.08923756331205368, 0.15134310722351074, 0.05681343004107475, -0.07703439891338348, -0.04101993516087532, 0.12316694855690002, 0.04273068904876709, -0.002827882766723633, 0.1775536686182022, -0.0400366447865963, 0.08013640344142914, -0.07719250023365021, 0.04037072882056236, -0.034494396299123764, 0.16161943972110748, 0.060993507504463196, 0.08672226220369339, 0.013320538215339184, 0.018887223675847054, -0.024415334686636925, -0.01919649727642536, -0.06448262184858322, -0.011393629014492035, 0.14491449296474457, 0.004014608915895224, -1.5242793938849963e-32, -0.2716854512691498, 0.12204819172620773, -0.01781827211380005, 0.02367999590933323, -0.10948426276445389, 0.036505650728940964, -0.047581423074007034, 0.18717209994792938, 0.11692150682210922, 0.0890892967581749, 0.004832137376070023, 0.06655309349298477, -0.16737055778503418, 0.01989656873047352, 0.022073345258831978, 0.07012251764535904, 0.1430947184562683, -0.17494553327560425, -0.17547185719013214, -0.09611749649047852, 0.02719036489725113, 0.11942283064126968, -0.19553601741790771, 0.1921684741973877, 0.053626686334609985, -0.001873504719696939, 0.10441424697637558, 0.21715837717056274, -0.0597924143075943, -0.12600143253803253, 0.05665890872478485, -0.026614805683493614, -0.03898234665393829, 0.0031212717294692993, 0.05606672167778015, -0.10715470463037491, 0.15079265832901, 0.19149748980998993, -0.09688412398099899, 0.002284238813444972, 0.02453792281448841, -0.10802692174911499, 0.02843409776687622, 0.05749066174030304, -0.0053216852247715, 0.0012517970753833652, -0.011695989407598972, -0.07719377428293228, 0.21908599138259888, 0.026798086240887642, -0.11867398023605347, 0.03026656247675419, 0.09943417459726334, 0.24899409711360931, -0.16159652173519135, 0.10499183088541031, 0.08011490106582642, 0.12282278388738632, 0.10811641067266464, 0.028875017538666725, 0.04756994917988777, 0.15862494707107544, -0.08667577058076859, -0.01921188458800316, 0.07456014305353165, -0.06377314776182175, 0.052591320127248764, -0.016426382586359978, -0.11077344417572021, 0.0028097096364945173, 0.06646338105201721, -0.017863616347312927, -0.08880292624235153, -0.3338761329650879, 0.08637606352567673, 0.10390519350767136, 0.024470103904604912, 0.06110503897070885, -0.08611788600683212, 0.0017765350639820099, -0.01326401624828577, -0.07410669326782227, -0.025096789002418518, 0.006117085460573435, -0.03907368332147598, -0.09517506510019302, 0.15063011646270752, -0.05066988989710808, -0.06062334403395653, 0.02784089744091034, -0.11323961615562439, -0.2347453385591507, -0.1286027580499649, 0.00705467164516449, 0.010685683228075504, -9.938548828358762e-08, -0.014988909475505352, -0.049451518803834915, -0.06648796051740646, -0.04078924283385277, 0.11779827624559402, 0.10569995641708374, 0.036825332790613174, 0.03281252086162567, -0.017629051581025124, 0.2648875117301941, 0.07513496279716492, -0.12680457532405853, -0.1841181516647339, -0.16824740171432495, 0.06792153418064117, -0.05416576936841011, -0.014849585480988026, 0.050803665071725845, -0.010278035886585712, -0.20521420240402222, 0.15391607582569122, 0.12705136835575104, 0.3285304605960846, -0.23880308866500854, 0.03779647871851921, -0.021303443238139153, 0.10162555426359177, 0.027019863948225975, 0.03986750543117523, -0.004332596901804209, -0.1333083063364029, 0.12795190513134003, -0.1583700031042099, -0.13838060200214386, 0.020259318873286247, 0.16383646428585052, 0.02402411215007305, 0.0796503871679306, 0.07581871002912521, 0.05098533257842064, 0.022580215707421303, -0.1764240711927414, 0.0444820411503315, 0.13371682167053223, -0.01993853785097599, 0.22019022703170776, -0.11030775308609009, -0.048829566687345505, 0.26009291410446167, -0.11872819811105728, 0.02471284754574299, -0.1344633400440216, 0.11869295686483383, 0.05762098357081413, -0.1490771472454071, 0.14506565034389496, 0.018364248797297478, 0.045138079673051834, -0.1328093558549881, 0.12332066148519516, 0.1700328141450882, -0.27577337622642517, -0.027379585430026054, 0.14403977990150452], "changes": {"1wk": -13.15789583757421, "1mo": -19.883042444083177}}]